Tech Company M&A Transactions
Heptares Therapeutics Acquisition
Heptares Therapeutics was bought by Sosei Group. The transaction was announced on 2/23/2015. Sosei Group said the transaction price was $400 million.
Transaction Overview
Company Name
Acquired By
Announced On
2/23/2015
Transaction Type
M&A
Amount
$400,000,000
M&A Terms
Sosei has acquired 100% of Heptares' share capital for USD 180 million in cash consideration and up to USD 220 million contingent upon the successful progression of the company's pipeline and platform.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
Bio Park Broadwater Road
Welwyn Garden City Hertfordshire, AL7 3AX
UK
Welwyn Garden City Hertfordshire, AL7 3AX
UK
Phone
Website
Email Address
Overview
Heptares creates new medicines targeting previously undruggable or challenging GPCRs, a superfamily of receptors linked to many diseases. We are pioneering a structure-based drug design approach to GPCRs, leveraging proprietary technologies for protein stabilisation, structure determination, and fragment-based discovery.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Malcolm Weir
Chief Medical Officer
Tim Tasker
Chief Scientific Officer
Fiona Marshall
President
Daniel Grau
Browse more venture capital transactions:
Prev: 2/23/2015: Leankor venture capital transaction
Next: 2/23/2015: Iagnosis venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs